# Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines

> **NCT00698490** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 130 (actual)

## Conditions studied

- Prophylaxis Herpes Simplex

## Interventions

- **BIOLOGICAL:** Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141
- **BIOLOGICAL:** Herpes simplex virus containing gD-Alum

## Key facts

- **NCT ID:** NCT00698490
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-08
- **Primary completion:** 1997-01
- **Final completion:** 1997-01
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2008-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698490, "Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00698490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*